Michele A Kutzler1, Jeffrey M Jacobson. 1. Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Abstract
PURPOSE OF REVIEW: Introduction of potent combination antiretroviral therapy has led to the successful treatment of HIV infection, although adverse side effects, toxicities and drug resistance to currently available antiretroviral therapy regimens emerge, resulting in poorer outcomes. Alternative therapeutic interventions are needed to enhance HIV-1-specific immunity. The review will discuss the rationale for use of therapeutic immunization as a method to enhance HIV-1-specific immunity, and support the use of analytical treatment interruption to obtain and define immune correlates. RECENT FINDINGS: Results of recent studies using structured treatment interruption strategies demonstrate that with proper features to protect against drug resistance and drops in CD4 cell counts, viral endpoints following analytical treatment interruption can be used as a tool for measuring efficacy of immunologic therapeutic interventions. The viral rebound dynamics during and viral set points established following analytical treatment interruptions should be used as study endpoints as they represents the host's anti-HIV immune response to the therapeutic vaccine. SUMMARY: The results of recent treatment interruption studies support the use of an analytical treatment interruption as an effective tool to identify and define immune function correlates, and to generate data to support the subsequent conduct of larger, more definitive phase II/III studies.
PURPOSE OF REVIEW: Introduction of potent combination antiretroviral therapy has led to the successful treatment of HIV infection, although adverse side effects, toxicities and drug resistance to currently available antiretroviral therapy regimens emerge, resulting in poorer outcomes. Alternative therapeutic interventions are needed to enhance HIV-1-specific immunity. The review will discuss the rationale for use of therapeutic immunization as a method to enhance HIV-1-specific immunity, and support the use of analytical treatment interruption to obtain and define immune correlates. RECENT FINDINGS: Results of recent studies using structured treatment interruption strategies demonstrate that with proper features to protect against drug resistance and drops in CD4 cell counts, viral endpoints following analytical treatment interruption can be used as a tool for measuring efficacy of immunologic therapeutic interventions. The viral rebound dynamics during and viral set points established following analytical treatment interruptions should be used as study endpoints as they represents the host's anti-HIV immune response to the therapeutic vaccine. SUMMARY: The results of recent treatment interruption studies support the use of an analytical treatment interruption as an effective tool to identify and define immune function correlates, and to generate data to support the subsequent conduct of larger, more definitive phase II/III studies.
Authors: Jeffrey M Jacobson; Jean-Pierre Routy; Seth Welles; Mark DeBenedette; Irina Tcherepanova; Jonathan B Angel; David M Asmuth; David K Stein; Jean-Guy Baril; Mehri McKellar; David M Margolis; Benoit Trottier; Kenneth Wood; Charles Nicolette Journal: J Acquir Immune Defic Syndr Date: 2016-05-01 Impact factor: 3.731
Authors: D Brenda Salantes; Yu Zheng; Felicity Mampe; Tuhina Srivastava; Subul Beg; Jun Lai; Jonathan Z Li; Randall L Tressler; Richard A Koup; James Hoxie; Mohamed Abdel-Mohsen; Scott Sherrill-Mix; Kevin McCormick; E Turner Overton; Frederic D Bushman; Gerald H Learn; Robert F Siliciano; Janet M Siliciano; Pablo Tebas; Katharine J Bar Journal: J Clin Invest Date: 2018-06-18 Impact factor: 14.808
Authors: Marie-Angélique De Scheerder; Clarissa Van Hecke; Henrik Zetterberg; Dietmar Fuchs; Nele De Langhe; Sofie Rutsaert; Bram Vrancken; Wim Trypsteen; Ytse Noppe; Bea Van Der Gucht; Jolanda Pelgrom; Filip Van Wanzeele; Sarah Palmer; Philippe Lemey; Magnus Gisslén; Linos Vandekerckhove Journal: J Antimicrob Chemother Date: 2020-05-01 Impact factor: 5.790
Authors: Ronald J Bosch; Richard B Pollard; Alan Landay; Evgenia Aga; Lawrence Fox; Ronald Mitsuyasu Journal: J Interferon Cytokine Res Date: 2011-02-03 Impact factor: 2.607
Authors: Eric S Rosenberg; Barney S Graham; Ellen S Chan; Ronald J Bosch; Vicki Stocker; Janine Maenza; Martin Markowitz; Susan Little; Paul E Sax; Ann C Collier; Gary Nabel; Suzanne Saindon; Theresa Flynn; Daniel Kuritzkes; Dan H Barouch Journal: PLoS One Date: 2010-05-10 Impact factor: 3.240
Authors: Jeffrey M Jacobson; Lu Zheng; Cara C Wilson; Pablo Tebas; Roy M Matining; Michael A Egan; John Eldridge; Alan L Landay; David B Clifford; Anne F Luetkemeyer; Jennifer Tiu; Ana L Martinez; Jennifer Janik; Teresa A Spitz; John Hural; Juliana McElrath; Nicole Frahm Journal: J Acquir Immune Defic Syndr Date: 2016-02-01 Impact factor: 3.731